Lisata wins FDA orphan drug status for bone cancer candidate
The FDA has granted orphan drug designation for Lisata Therapeutics’s LSTA1 (certepetide) to treat osteosarcoma, a rare type of blood cancer.
The FDA has granted orphan drug designation for Lisata Therapeutics’s LSTA1 (certepetide) to treat osteosarcoma, a rare type of blood cancer.
What's Your Reaction?
